Diabetic Retinopathy: Vision Loss Prevention & Treatment

Diabetic retinopathy (DR) is the leading cause of vision loss in working-age adults. It results from chronic hyperglycemia damaging retinal microvasculature.

Pathophysiology

  • Hyperglycemia → ↑polyol pathway, ↑AGEs, ↑PKC, ↑hexosamine → pericyte loss, basement membrane thickening, endothelial dysfunction → capillary occlusion, leakage, ischemia.
  • Ischemia → ↑VEGF → neovascularization (fragile, leaky).

Classification (ETDRS / ICDR)

StageFindingsVision Risk
No DRNormal examNone
Mild NPDRMicroaneurysms onlyLow
Moderate NPDRMicroaneurysms + dot/blot hemorrhages, hard exudates, cotton wool spotsModerate
Severe NPDR4-2-1 rule: hemorrhages 4 quadrants, venous beading 2+, IRMA 1+High (↑PDR risk)
PDRNeovascularization (NVD, NVE), vitreous hemorrhage, traction retinal detachmentVery High
Diabetic Macular Edema (DME)Retinal thickening near fovea (CSME)Central vision loss; can occur at any stage

Risk Factors

  • Duration of diabetes (strongest).
  • Glycemic control (HbA1c) – each 1% ↓ → ~35% ↓DR progression (DCCT/UKPDS).
  • Hypertension, dyslipidemia, nephropathy, pregnancy, anemia, smoking.

Screening & Early Detection

  • T1D: First exam 5 yrs after diagnosis, then annually.
  • T2D: First exam at diagnosis, then annually.
  • Pregnancy: Preconception/1st tri, each trimester, 1 yr postpartum.
  • Dilated fundus exam ± retinal photography/OCT.

Treatment

  • DME: Anti-VEGF (aflibercept, ranibizumab, bevacizumab) first-line; steroid implants; laser (focal/grid).
  • PDR: Panretinal photocoagulation (PRP) ± anti-VEGF; vitrectomy for VH/TRD.
  • Systemic: Intensive glycemic/BP/lipid control slows progression.

Key Message

Vision loss from DR is largely preventable with timely screening and treatment. Patient adherence to eye exams is the critical gap.

Eye & Vision Disorders - Related Articles